Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 29;51(1):14. doi: 10.3892/or.2023.8673

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Ye et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — High SYNPO2 expression is a poor prognostic factor in BLCA. (A) Overall survival in patients with BLCA with low (n=206) and high (n=205) SYNPO2 expression. (B) Disease-specific survival in patients with BLCA in low (n=200) and high (n=179) SYNPO2 expression groups. (C) Progression-free interval for patients based on SYNPO2 expression (low, n=206; high, n=206). (D) Distribution of SYNPO2 expression in BLCA samples from patients at different stages. Stage I and stage II (n=133), stage III (n=142), stage IV (n=135). Stage I and II vs. stage III, P.adj=0.0125, stage I and II vs, stage IV P.adj=7.47×1005. (E) Distribution of SYNPO2 expression in patients with BLCA at different T stages. T1 and T2 (n=123) vs. T3 and T4 (n=255), P=0.0014. (F) SYNPO2 expression in patients with BLCA at different N stages. N0 (n=238) vs. N1, N2 and N3 (n=130), P=0.0012. (G) SYNPO2 expression in BLCA samples of non-papillary (n=273) and papillary (n=134) subtypes. P=0.0008. (H) SYNPO2 expression in patients with BLCA with (n=129) or without (n=152) lymphovascular invasion. P=0.0238. (I) Representative immunohistochemistry of Ki67 and SYNPO2 staining in BLCA tissue with low and high SYNPO2 expression. (J) Spearman correlation analysis of Ki67 and SYNPO2 expression (n=45). (K) Nomogram based on multivariate Cox regression analysis for 1 and 3-year survival probability. SYNPO2, synaptopodin-2; BLCA, Bladder Urothelial Carcinoma; TPM, Transcript per million. *, ** and *** indicate P<0.05, P<0. 01, P<0.001, respectively.